While the effects of CDK7 inhibitors on breast cancer are not yet fully understood, CDK7 is known to play a dual role in cell cycle progression and transcription initiation by phosphorylating RNA polymerase II and priming cell cycle CDKs for activation, making it an attractive therapeutic target162. Here, CDK7 is linked to breast cancer.